Perry C. Siatis - Feb 2, 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)

Signature
T.O. Odutayo, attorney-in-fact for Perry C. Siatis
Stock symbol
ABBV
Transactions as of
Feb 2, 2024
Transactions value $
-$496,230
Form type
4
Date filed
2/6/2024, 05:00 PM
Previous filing
Apr 5, 2023
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Award $422K +2.92K +28.13% $144.54 13.3K Feb 2, 2024 Direct
transaction ABBV Common Stock, $0.01 par value Disposed to Issuer -$496K -2.92K -21.95% $170.00 10.4K Feb 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Options Exercise -$422K -2.92K -33.34% $144.54 5.84K Feb 2, 2024 Common Stock 2.92K $144.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on February 14, 2023.
F2 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.